Cat. No.: HY-N0144

Piperine

(Synonyms: Bioperine; 1-Piperoylpiperidine)

17 Cited Publications

Customer Review

Based on 17 publication(s) in Google Scholar

Piperine is an alkaloid, can be isolated from pepper. Piperine can inhibit the activity of P-glycoprotein and CYP3A4. Piperine inhibits HeLa cells with an IC₅₀ of 61.94±0.054 μg/mL.

For research use only. We do not sell to patients.

Purity: 98.99%
CAS No.: 94-62-2
Formula: C₁₇H₁₉NO₃
Molecular Weight:285.34

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Piperine Chemical Structure

CAS No.: 94-62-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Piperine is an alkaloid, can be isolated from pepper. Piperine can inhibit the activity of P-glycoprotein and CYP3A4. Piperine inhibits HeLa cells with an IC₅₀ of 61.94±0.054 μg/mL^[1]^[2]^[3].

IC₅₀ & Target

IC50: 61.94±0.054 μg/mL (P-glycoprotein, HeLa cell)^[1]

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.89 μM Compound: Piperine	Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay Antiproliferative activity in human A549 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay	[PMID: 30108756]
Bel-7402	IC₅₀	>10 μM Compound: Piperine	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
BTI-TN-5B1-4	IC₅₀	1.05 μM Compound: 1	Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho	[PMID: 31711793]
Caco-2	IC₅₀	15.5 μM Compound: Piperine	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	[PMID: 12130727]
Caco-2	IC₅₀	74.1 μM Compound: Piperine	TP_TRANSPORTER: inhibition of Cyclosporin A transepithelial transport (basal to apical) (Cyclosporin A: 1 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Cyclosporin A transepithelial transport (basal to apical) (Cyclosporin A: 1 uM) in Caco-2 cells	[PMID: 12130727]
COLO 205	IC₅₀	46 μM Compound: 1	Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay	10.1007/s00044-010-9500-5
DLD-1	IC₅₀	<200 μM Compound: 58	Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Anticancer activity against human DLD-1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 33445154]
DU-145	IC₅₀	>50 μM Compound: 1	Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay	10.1007/s00044-010-9500-5
HCT-116	IC₅₀	<200 μM Compound: 58	Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 33445154]
HeLa	IC₅₀	19.21 μM Compound: Piperine	Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay Antiproliferative activity in human HeLa cells assessed as reduction in cell number incubated for 48 hrs by SRB assay	[PMID: 30108756]
HeLa	IC₅₀	0.95 μM Compound: 1	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-013-0541-4
HeLa	IC₅₀	0.95 μmol Compound: 1	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-013-0541-4
HEp-2	IC₅₀	70 μM Compound: 1	Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay	10.1007/s00044-010-9500-5
Hepatocyte	IC₅₀	12 μM Compound: 10	Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control	[PMID: 19775895]
HepG2	IC₅₀	>10 μM Compound: Piperine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HepG2 2.2.15	CC₅₀	2.35 mM Compound: 7	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 23434420]
HepG2 2.2.15	IC₅₀	0.14 mM Compound: 7	Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion	[PMID: 23434420]
HepG2 2.2.15	IC₅₀	0.15 mM Compound: 7	Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion	[PMID: 23434420]
HUVEC	IC₅₀	100 μM Compound: Piperine	Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM-1 expression incubated for 2 hrs prior to TNFalpha challenge measured after 16 hrs by ELISA	10.1039/C2MD20216F
IMR-32	IC₅₀	10.19 μM Compound: Piperine	Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay Antiproliferative activity in human IMR32 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay	[PMID: 30108756]
IMR-32	IC₅₀	89 μM Compound: 1	Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay	10.1007/s00044-010-9500-5
L929	IC₅₀	42 μM Compound: 10	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control	[PMID: 19775895]
MCF7	IC₅₀	12.96 μM Compound: Piperine	Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay Antiproliferative activity in human MCF7 cells assessed as reduction in cell number incubated for 48 hrs by SRB assay	[PMID: 30108756]
MCF7	IC₅₀	99 μM Compound: 1	Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay	10.1007/s00044-010-9500-5
MCF7	IC₅₀	0.99 μM Compound: 1	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	10.1007/s00044-013-0541-4
MCF7	IC₅₀	0.99 μmol Compound: 1	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	10.1007/s00044-013-0541-4
MDA-MB-231	IC₅₀	58.45 μg/mL Compound: 3	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0397-z
Oocyte	EC₅₀	52 μM Compound: 5	Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay Activation of rat GABA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as potentiation of GABA-induced chloride current after 90 secs by two microplate electrode voltage clamp assay	[PMID: 20085307]
PC-3	IC₅₀	>50 μM Compound: 1	Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay	10.1007/s00044-010-9500-5
SW480	IC₅₀	<200 μM Compound: 58	Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 33445154]
WI-38	IC₅₀	8.8 μM Compound: 2	Induction of senescence in human WI-38 cells Induction of senescence in human WI-38 cells	[PMID: 38436272]

In Vitro

Piperine has shown to possess in vitro cytotoxic activity and in silico studies. The IC₅₀ value is found to be 61.94±0.054 μg/mL and in silico studies, it has more number of hydrogen bonds with minimum binding and docking energy and may be considered as inhibitor of EGFR tyrosine kinase^[1]. Piperine has been found to have immunomodulatory, anti-oxidant, anti-asthmatic, anti-carcinogenic, anti-inflammatory, anti-ulcer, and anti-amoebic properties^[2]. Piperine could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

At the dose of 3.5 mg/kg, the bioavailability of piperine is calculated to be 25.36%. Its AUC_0→t is unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of piperine. It is found that the AUC_0→t and C₀ of Docetaxel (HY-B0011) and t_1/2 of piperine are significantly increased after their combination use, suggesting potential enhanced bioavailability of not only Docetaxel but also Piperine, which may lead to the overall enhanced pharmacological effects^[3]. The phosphorylation of I-κB, p65, p38, ERK, and JNK is inhibited by piperine in a dose-dependent manner, indicating that piperine may be a potential anti-inflammatory drug both in endometritis and in other S. aureus-induced diseases^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 94-62-2
Appearance Solid
Molecular Weight 285.34
Formula C₁₇H₁₉NO₃
Color White to light yellow
SMILES

O=C(N1CCCCC1)/C=C/C=C/C2=CC=C(OCO3)C3=C2
Synonyms

Bioperine; 1-Piperoylpiperidine
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (17)

All WB

Sort by:

Journal Impact Factor

Phytomedicine

Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis. [Abstract]

2025 Sep 25:148:157332. PMID: 41061292
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
PLoS Biol

Molecular mechanism of the tree shrew's insensitivity to spiciness. [Abstract]

2018 Jul 12;16(7):e2004921. PMID: 30001322
Phytother Res

Piperine attenuates the inflammation, oxidative stress, and pyroptosis to facilitate recovery from spinal cord injury via autophagy enhancement. [Abstract]

2023 Feb;37(2):438-451. PMID: 36114802
Food Biosci

2025 Apr.
Chin Med

Identification of anti-fibrotic compounds from Piper longum L via hollow fiber cell fishing and high-performance liquid chromatography with in vivo and in vitro validation. [Abstract]

2025 Aug 19;20(1):127. PMID: 40830877
Int Immunopharmacol

Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome. [Abstract]

2018 Dec:65:448-457. PMID: 30388519

Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457. [Abstract]

Piperine inhibits the activation of NLRP3 inflammasome. The protein levels of indicated targets are examined by Western blot.

Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457. [Abstract]

Piperine targets NLRP3 inflammasome in HK-2 cells. The protein levels of indicated proteins in cell lysates and from culture medium are examined by Western blot.

Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457. [Abstract]

Piperine inhibits AMPK activation. HK-2 cells are treated as indicated and the levels of p-AMPK, total AMPK, and β-tubulin are examined by Western blot.

Piperine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Dec:65:448-457. [Abstract]

Piperine targets NLRP3 inflammasome by blocking AMPK activation. HK-2 cells are treated as indicated.
Sci Rep

Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications. [Abstract]

2025 Nov 21;15(1):41324. PMID: 41271794
Microb Pathog

Effect of piperine on the inhibitory potential of MexAB-OprM efflux pump and imipenem resistance in carbapenem-resistant Pseudomonas aeruginosa. [Abstract]

2023 Dec:185:106397. PMID: 37852553
Saudi Pharm J

Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line. [Abstract]

2024 May;32(5):102064. PMID: 38633710
J Neurosci Res

Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein. [Abstract]

2019 Dec;97(12):1689-1705. PMID: 31420910
J Tradit Complement Med

Curcumin alone not combined with piperine exerts cardioprotective effects in pressure-overload rats by increasing glucagon-like peptide-1 receptor signaling and additional properties. [Abstract]

2024 Jul 26;15(5):522-535. PMID: 40979478
J Orthop Surg Res

The mechanism by which Naru 3 pill protects against intervertebral disc cartilage endplate degeneration based on network pharmacology and experimental verification. [Abstract]

2023 Jul 31;18(1):552. PMID: 37525208
Biochem Biophys Res Commun

A distinct structural mechanism underlies TRPV1 activation by piperine. [Abstract]

2019 Aug 20;516(2):365-372. PMID: 31213294
J Ocul Pharmacol Ther

Mechanisms Underlying the Protective Effects of Piperine on Retinal Pigment Epithelium Cells. [Abstract]

2025 Oct 13. PMID: 41084282
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363
Research Square Preprint

2021 Mar.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (175.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5046 mL

17.5230 mL

35.0459 mL

5 mM

0.7009 mL

3.5046 mL

7.0092 mL

10 mM

0.3505 mL

1.7523 mL

3.5046 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

Standard solution is prepared by dissolving 10 mg of piperine in 100 mL of methanol. The MTT assay is carried out to measure cell viability. Ten thousand cells in 100 μL of DMEM media are seeded in the wells of a 96-well plate. After 24 h, existing media is removed and 100 μL of various concentrations of piperine (20–100 μg/mL) are added and incubated for 48 h at 37 °C in a CO₂ incubator. Control cells are supplemented with 0.05 % DMSO vehicle. At the 48th hour of incubation, MTT (10 μL of 5 mg/mL) is added to the plate. The contents of the plate are pipetted out carefully, the formazan crystals formed are dissolved in 100 μL of DMSO, and the absorbance is measured at 550 nm in a microplate reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Rats: The stock solutions of piperine (PIP) and docetaxel (DOX)are prepared by dissolving appropriate amount of each authentic compound in DMSO separately at 1 mg/mL. The standard solutions containing both PIP and DOX are prepared by serial dilution of the stock solutions with 0.2% formic acid and acetonitrile (50:50, v/v) to yield concentrations of 25, 50, 100, 200, 400, 800, 1600, 3200, 6400, 12800 ng/mL. 25 Sprague-Dawley rats are divided into five groups receiving DOX(Group DOX 7 iv, 7 mg/kg, i.v.), PIP (Group PIP 35 po, 35 mg/kg,p.o.) and their combined administration (Group DOX+PIP) as well as PIP (Group PIP 3.5 po, 3.5 mg/kg, p.o.) and PIP (Group PIP 3.5 iv, 3.5 mg/kg, i.v.)^[3].

Mice: Piperine is dissolved in 5 mL of tris buffered saline (TBS) at concentrations corresponding to 25, 50, and 100 mg/kg, based on the weight of the mice. After 24 h of S. aureus infection in the uterus, the piperine solution is injected intraperitoneally three times every 6 h. A total of 60 female BALB/c mice are used in this study. All mice are maintained on a 12 h light/dark cycle and cafeteria feeding^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Portuguese - PT (537 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Paarakh PM, et al. In vitro cytotoxic and in silico activity of piperine isolated from Piper nigrum fruits Linn. In Silico Pharmacol. 2015 Dec;3(1):9. Epub 2015 Oct 29. [Content Brief]

[2]. Meghwal M,et al. Piper nigrum and piperine: an update. Phytother Res. 2013 Aug;27(8):1121-30. [Content Brief]

[3]. Li C, et al. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. J Pharm Biomed Anal. 2016 Sep 5;128:286-93. [Content Brief]

[4]. Zhai WJ, et al. Piperine Plays an Anti-Inflammatory Role in Staphylococcus aureus Endometritis by Inhibiting Activation of NF-κB and MAPK Pathways in Mice. Evid Based Complement Alternat Med. 2016;2016:8597208. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5046 mL	17.5230 mL	35.0459 mL	87.6148 mL
	5 mM	0.7009 mL	3.5046 mL	7.0092 mL	17.5230 mL
	10 mM	0.3505 mL	1.7523 mL	3.5046 mL	8.7615 mL
	15 mM	0.2336 mL	1.1682 mL	2.3364 mL	5.8410 mL
	20 mM	0.1752 mL	0.8761 mL	1.7523 mL	4.3807 mL
	25 mM	0.1402 mL	0.7009 mL	1.4018 mL	3.5046 mL
	30 mM	0.1168 mL	0.5841 mL	1.1682 mL	2.9205 mL
	40 mM	0.0876 mL	0.4381 mL	0.8761 mL	2.1904 mL
	50 mM	0.0701 mL	0.3505 mL	0.7009 mL	1.7523 mL
	60 mM	0.0584 mL	0.2920 mL	0.5841 mL	1.4602 mL
	80 mM	0.0438 mL	0.2190 mL	0.4381 mL	1.0952 mL
	100 mM	0.0350 mL	0.1752 mL	0.3505 mL	0.8761 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Piperine

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Food Additive Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Pesticide Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Flavors and Fragrances Compound Library

Natural Product Diversity Scaffold Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Piperine

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (17)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Piperine Related Classifications

Cat. No.: HY-N0144